Viva Biotech Dispenses Bitter Pill of Slowing Growth, Asset Devaluation
The contract drug services provider lost roughly 100 million yuan in the first half of this year, as its revenue growth underperformed its peers Key Takeaways: Viva Biotech’s eked out…
